Recro Pharma, a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, has signed additional agreements with an existing customer, Ensysce Biosciences. Under these new agreements, Recro will provide early-stage development and manufacturing services to support two of Ensysce’s development programs. Recro and Ensysce have already commenced the initial phase of these projects.
 
“We are delighted that Ensysce has elected to expand our relationship by selecting Recro as their CDMO to support the development of these important drug candidates,” said Richard Sidwell, chief scientific officer, Recro. “The ability to partner with a company that is committed to applying its proprietary technology platform to addressing the ongoing opioid crisis in a novel way is a privilege to the entire Recro team.”
 
Lynn Kirkpatrick, chief executive officer, Ensysce Biosciences, said, “Ensysce is happy to partner with Recro to advance the development of our clinical programs. Recro’s experience with oral solid dosage forms, positive track record with regulatory agencies, and high touch partnership approach to working with customers will support our efforts to bring novel, abuse and overdose resistant relief to patients suffering from chronic pain.”